Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 14 for:    asthma | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | "vitamin d"

Vitamin D Oral Replacement in Asthma (VDORA1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03686150
Recruitment Status : Recruiting
First Posted : September 26, 2018
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
IDeA States Pediatric Clinical Trials Network

Brief Summary:
The overall objective of the study is to determine the pharmacokinetics of Vitamin D supplementation in children who have asthma and are overweight or obese.

Condition or disease Intervention/treatment Phase
Asthma Vitamin D Deficiency Pediatric Obesity Dietary Supplement: Vitamin D3 oral regimen Not Applicable

Detailed Description:

This study has two parts. In part 1, study participants will be randomized to receive one of four doses of vitamin D supplementation in international units (IU) over at 16-week period: 1) Single 50,000 IU loading dose + 6000 IU daily dose; 2) Single 50,000 IU loading dose + 10,000 IU daily dose: 3) 6000 IU daily dose; or 4) 600 IU daily dose. Based on pharmacokinetic analysis, one of the doses (1-3) will be selected to use in part 2.

In part 2, study participants will be randomized to the dose selected in part 1 or the 600 IU daily dose of vitamin D supplementation to be administered over a 16-week dosing period.

Across both parts, safety of each dose regimen of vitamin D supplementation will be evaluated, and the effectiveness of each dose to achieve a serum level of 25(OH)D greater than or equal to 40 ng/ml will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, parallel arm clinical trial 4 arms in part 1 2 arms in part 2
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Vitamin D Oral Replacement in Asthma
Actual Study Start Date : January 30, 2019
Estimated Primary Completion Date : October 31, 2021
Estimated Study Completion Date : October 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Vitamin D

Arm Intervention/treatment
Experimental: Part 1, Cohort 1 Vitamin D3 oral regimen
Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
Dietary Supplement: Vitamin D3 oral regimen
Vitamin D3 oral regimens supplementation

Experimental: Part 1, Cohort 2 Vitamin D3 oral regimen
Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
Dietary Supplement: Vitamin D3 oral regimen
Vitamin D3 oral regimens supplementation

Experimental: Part 1, Cohort 3 Vitamin D3 oral regimen
Vitamin D: 6000 IU daily dose
Dietary Supplement: Vitamin D3 oral regimen
Vitamin D3 oral regimens supplementation

Active Comparator: Part 1, Cohort 4 Vitamin D3 oral regimen
Vitamin D: 600 IU daily dose
Dietary Supplement: Vitamin D3 oral regimen
Vitamin D3 oral regimens supplementation

Experimental: Part 2, Cohort A Vitamin D3 oral regimen
Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
Dietary Supplement: Vitamin D3 oral regimen
Vitamin D3 oral regimens supplementation

Active Comparator: Part 2, Cohort B Vitamin D oral regimen
Vitamin D: 600 IU daily dose
Dietary Supplement: Vitamin D3 oral regimen
Vitamin D3 oral regimens supplementation




Primary Outcome Measures :
  1. Best dosing level of vitamin D supplementation [ Time Frame: 20 weeks ]
    Determine the best vitamin D supplementation level based on PK analysis

  2. Part 1: optimal dosing level to use in part 2 [ Time Frame: 20 weeks ]
    Based on part 1 data, determine the best vitamin D supplementation level based on PK analysis

  3. Part 2: Proportion of participants with vitamin D levels >= 40 ng/ml [ Time Frame: 16 weeks ]
    Proportion of participants in part 2 who achieve vitamin levels >= 40 ng/ml



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body mass index greater than or equal to 85% for age and sex
  • Physician-diagnosed asthma
  • Ongoing relationship with asthma provider responsible for asthma care
  • Serum 25(OH) D level 10 ng/ml to less than 30 ng/ml at screening visit based on local laboratory test
  • Ability to swallow pills similar in size to the vitamin D preparation to be used
  • Signed consent form from parent, legal guardian or caregiver and signed assent from participant (as appropriate)
  • Females of childbearing years must not be pregnant, must not be lactating and must agree to practice adequate birth control method
  • Child and parent, legal guardian, or caregiver must speak English or Spanish

Exclusion Criteria:

  • Known diseases of calcium metabolism or the parathyroid
  • History of renal insufficiency or kidney stones
  • Known liver failure or history of abnormal liver function tests
  • History of Williams syndrome, sarcoidosis, or granulomatous disease
  • Active tuberculosis
  • Spot urine calcium/creatinine ration greater than 0.37 (calcium and creatinine measured in mg/ml). This can be repeated following adequate hydration
  • Clinical evidence of rickets
  • Taking supplemental vitamin D greater than equal to 1000 IU per day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03686150


Contacts
Layout table for location contacts
Contact: Jeannette Y Lee, Ph.D. 501 320 7344 jylee@uams.edu
Contact: Jessica Snowden, MD 501 526 5837 jsnowden@uams.edu

Locations
Layout table for location information
United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 72202
Contact: Tamara Perry, MD         
United States, Delaware
Nemours/Alfred I duPont Hospital for Children Recruiting
Wilmington, Delaware, United States, 19803
Contact: Aaron Chidekel, MD         
United States, Hawaii
Kapiolani Medical Center for Women and Children Recruiting
Honolulu, Hawaii, United States, 96826
Contact: Brian Wu, MD         
United States, Kentucky
University of Louisville Recruiting
Louisville, Kentucky, United States, 40292
Contact: Sara Watson, MD, MS         
United States, Louisiana
Pennington Biomedical Research Center Recruiting
Baton Rouge, Louisiana, United States, 70808
Contact: Daniel Hsia, MD         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: David Josey, MD         
United States, Missouri
Children's Mercy Hospital Recruiting
Kansas City, Missouri, United States, 64108
Contact: Jade Tam-Williams, MD         
United States, Montana
Community Medical Center Recruiting
Missoula, Montana, United States, 59804
Contact: Paul G Smith, DO,FAAP,FACOP         
United States, Nebraska
University of Nebraska Medical Center/Children's Hospital and Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Hana Niebur, MD, OD         
United States, New Hampshire
Dartmouth Hospital - Manchester Recruiting
Manchester, New Hampshire, United States, 03104
Contact: Margaret F Guill, MD         
United States, New Mexico
University of New Mexico Health Sciences Center Recruiting
Albuquerque, New Mexico, United States, 87131
Contact: Hengameh Raissy, PharmD         
United States, Oklahoma
Children's Hospital OU Medical Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Nighat Medhi, MD         
United States, South Carolina
University of South Carolina Recruiting
Columbia, South Carolina, United States, 29208
Contact: Lisa Knight, MD         
United States, Vermont
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Lauren Faricy, MD         
Contact: Kelly Cowan, MD         
United States, West Virginia
West Virginia University Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Brian Ely, MD         
Contact: Lee Pyles, MD, MS         
Sponsors and Collaborators
IDeA States Pediatric Clinical Trials Network
Layout table for additonal information
Responsible Party: IDeA States Pediatric Clinical Trials Network
ClinicalTrials.gov Identifier: NCT03686150    
Other Study ID Numbers: 101
First Posted: September 26, 2018    Key Record Dates
Last Update Posted: August 20, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by IDeA States Pediatric Clinical Trials Network:
pediatric obesity
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Vitamin D
Vitamin D Deficiency
Pediatric Obesity
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Cholecalciferol
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents